Literature DB >> 27448441

A combined microRNA-based targeted therapeutic approach to eradicate glioblastoma stem-like cells.

Carla L Esposito1, Silvia Nuzzo1, Swati A Kumar2, Anna Rienzo1, Clare L Lawrence2, Roberto Pallini3, Lisa Shaw2, Jane E Alder2, Lucia Ricci-Vitiani4, Silvia Catuogno1, Vittorio de Franciscis5.   

Abstract

A minor population of glioblastoma stem-like cells (GSCs) has been implicated in the relapse and resistance of glioblastoma to therapeutic treatments. Based on knowledge of the involvement of multiple microRNAs in GSC propagation, we designed a combinational approach to target the GSC population with multiple miRNA-based therapeutics. As carriers for the targeted delivery we took advantage of two aptamers that bind to, and inhibit, the receptor tyrosine kinases, Axl and PDGFRβ. We showed that the aptamer conjugates are transported through an in vitro blood-brain barrier (BBB) model. Furthermore, combining miR-137 and antimiR-10b synergizes with the receptor inhibitory function of aptamer carriers and prevents GSC expansion. Results highlighted the potential of combining multifunctional RNA-based therapeutics for selective targeting of GSCs and offer a proof of principle strategy to potentially fulfill the still unmet need for effective and safe treatment of glioma.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aptamer; Cancer stem cells; Glioblastoma; Targeted delivery; microRNA

Mesh:

Substances:

Year:  2016        PMID: 27448441     DOI: 10.1016/j.jconrel.2016.07.032

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  29 in total

Review 1.  Aptamers as Therapeutic Agents: Has the Initial Euphoria Subsided?

Authors:  S K Haßel; G Mayer
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

Review 2.  RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Authors:  Eunice L Lozada-Delgado; Nilmary Grafals-Ruiz; Pablo E Vivas-Mejía
Journal:  Life Sci       Date:  2017-08-31       Impact factor: 5.037

Review 3.  Aptamers as Modular Components of Therapeutic Nucleic Acid Nanotechnology.

Authors:  Martin Panigaj; M Brittany Johnson; Weina Ke; Jessica McMillan; Ekaterina A Goncharova; Morgan Chandler; Kirill A Afonin
Journal:  ACS Nano       Date:  2019-11-05       Impact factor: 15.881

Review 4.  Cancer-Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery.

Authors:  Hannah J Vaughan; Jordan J Green; Stephany Y Tzeng
Journal:  Adv Mater       Date:  2019-06-20       Impact factor: 30.849

Review 5.  Aptamer-Mediated Targeted Delivery of Therapeutics: An Update.

Authors:  Silvia Catuogno; Carla L Esposito; Vittorio de Franciscis
Journal:  Pharmaceuticals (Basel)       Date:  2016-11-03

Review 6.  Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications.

Authors:  Emma M Hays; Wei Duan; Sarah Shigdar
Journal:  Int J Mol Sci       Date:  2017-11-30       Impact factor: 5.923

Review 7.  Current Advances in Aptamers for Cancer Diagnosis and Therapy.

Authors:  Shin-Ichiro Hori; Alberto Herrera; John J Rossi; Jiehua Zhou
Journal:  Cancers (Basel)       Date:  2018-01-03       Impact factor: 6.639

8.  STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma.

Authors:  Carla Lucia Esposito; Silvia Nuzzo; Silvia Catuogno; Simona Romano; Filomena de Nigris; Vittorio de Franciscis
Journal:  Mol Ther Nucleic Acids       Date:  2017-12-30       Impact factor: 8.886

9.  An anti-PDGFRβ aptamer for selective delivery of small therapeutic peptide to cardiac cells.

Authors:  Alessandra Romanelli; Alessandra Affinito; Concetta Avitabile; Silvia Catuogno; Paola Ceriotti; Margherita Iaboni; Jessica Modica; Geroloma Condorelli; Daniele Catalucci
Journal:  PLoS One       Date:  2018-03-07       Impact factor: 3.240

Review 10.  Aptamers: Cutting edge of cancer therapies.

Authors:  Sarah Shigdar; Brett Schrand; Paloma H Giangrande; Vittorio de Franciscis
Journal:  Mol Ther       Date:  2021-06-17       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.